Skip to main content
Carole Thang on Muck Rack

Carole Thang

As seen in: Wiley Online Library, Diabetes Care Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carole

Contact Carole, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

|
By Caroline Reilhac, Julie Dubourg, Carole Thang, Jean-Marie Grouin
| Wiley Online Library Verified
ORIGINAL ARTICLE Caroline Reilhac PhD, Caroline Reilhac PhD POXEL, 259/261 Avenue Jean Jaurès, Lyon, France Both authors have equally contributed to the manuscript. Search for more papers by this author Julie Dubourg MD, Julie Dubourg MD orcid.org/0000-0002-5514-8075 POXEL, 259/261 Avenue Jean Jaurès, Lyon, France Both authors have equally contributed to the manuscript.
Open in Who Shared Issue with article?

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

|
By Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin
| Diabetes Care Magazine Verified
Emerging Therapies: Drugs and Regimens Abstract OBJECTIVE The aim of this study was to investigate the efficacy and safety of imeglimin, the first in a new class of oral antidiabetic agent, in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This was a double-blind, randomized, parallel-group, placebo-controlled phase 3 trial in 30 sites in Japan.
Open in Who Shared Issue with article?

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

|
By Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin
| Diabetes Care Magazine Verified
Original Research Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki Abstract OBJECTIVE The aim of this study was to investigate the efficacy and safety of imeglimin, the first in a new class of oral antidiabetic agent, in Japanese patients with type 2 diabetes.
Open in Who Shared Issue with article?
See all 3 articles